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Objective. To estimate the proportion of patients
with axial spondyloarthritis (SpA) in a UK national bio-
logics registry who met criteria for fibromyalgia (FM),
and to delineate the characteristics of these patients.
Methods. Two cohorts of patients are prospec-
tively recruited from across 83 centers in the UK for the
British Society for Rheumatology Biologics Register in
Ankylosing Spondylitis (BSRBR-AS). All patients are
required to meet Assessment of SpondyloArthritis
international Society (ASAS) criteria for axial SpA.
Patients are either newly starting biologic therapy
(biologics cohort) or are naive to treatment with biologic
agents (non-biologics cohort) at the time of recruitment,
and all patients are followed up prospectively. At
recruitment and follow-up, clinical information and
measurements are recorded while patients complete the
2011 research criteria for FM and assessments of the
level of disease activity and work impact.
Results. Of the patients registered in the
BSRBR-AS, 1,504 (68% male) were eligible for the cur-
rent analysis, of whom 311 (20.7%) met the 2011
research criteria for FM. Prevalence of FM was simi-
lar between patients who fulfilled the modified New York
criteria for AS (19.7%) and those who fulfilled ASAS
imaging criteria but not the modified New York criteria
(25.2%); however, among those who fulfilled only the
ASAS clinical criteria, the prevalence of FM was lower
(9.5%). Patients who met FM criteria reported signifi-
cantly worse disease activity, function, global severity
scores, and quality of life, and were more likely to have
moderate or severe levels of mood disorder and clini-
cally important fatigue. Patients who met FM criteria
reported experiencing work impairment around half
their working time. Meeting FM criteria was not related
to elevated C-reactive protein levels or most extraspinal
manifestations, but was associated with a higher likeli-
hood of having received biologic therapy.
Conclusion. Developing management approaches
that would address the significant unmet clinical needs
of the 1 in 5 patients with axial SpA who meet criteria
for FM should be a research priority.
Fibromyalgia (FM) may be more common in
patients with axial spondyloarthritis (SpA) than in the
general population. In comparison to a population
prevalence of 2–4% based on the American College of
Rheumatology (ACR) 1990 criteria for FM (1), studies
in patients with ankylosing spondylitis (AS) from Tur-
key (prevalence 12.6%; n = 119), Italy (prevalence
12.7%; n = 211), and Brazil (prevalence 15%; n = 71)
have all shown a similar excess prevalence of FM
(2–4). This is consistent with the observation of a high
prevalence of FM in inflammatory rheumatic diseases
in general (5).
However, distinguishing axial SpA from FM is
problematic, given that the ACR 1990 criteria for FM
require the report of axial skeleton pain, which is the
key clinical feature of axial SpA, whereas enthesitis may
result in multisite pain, which is the cardinal feature of
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FM and is included in all established or proposed sets
of FM criteria (6–8). A pooled analysis of data from
clinical trials assessing treatment of patients with AS
with etanercept, sulfasalazine, or placebo has shown
higher disease burden and poorer response to treatment
in women (9,10). The trial investigators proposed that
these findings may be due to the concomitant presence
of FM, and identified comorbid FM as a priority for
future research.
FM may distort responses to some of the key
patient-reported measures used in axial SpA, such as
the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) and Bath Ankylosing Spondylitis Functional
Index (BASFI) (11,12). In the above-mentioned
study from Turkey in which AS patients with FM and
those without FM were compared, there was no differ-
ence in the C-reactive protein (CRP) level or erythro-
cyte sedimentation rate, but those with FM had higher
BASDAI scores (3). In July 2013, the US Food and
Drug Administration (FDA) met to consider whether
patients who had nonradiographic axial SpA, based on
the Assessment of SpondyloArthritis international Soci-
ety (ASAS) criteria (13), should be eligible for new
therapies. The FDA committee recognized the unmet
need for effective pharmacologic therapy for patients
who had either positive changes only on magnetic reso-
nance imaging (MRI) or positivity for HLA–B27 in
conjunction with other clinical and laboratory features
characteristic of SpA. The FDA was, however, con-
cerned about the possibility that those with highly
prevalent conditions such as mechanical back pain or
FM, especially patients without evidence of changes on
MRI, might be incorrectly diagnosed as having inflam-
matory spondylitis and could be inappropriately treated
with expensive and potentially toxic biologic therapies.
These observations highlight the need to better under-
stand the characteristics of patients who have overlap-
ping axial SpA and FM, to assess and distinguish the 2
conditions, and to develop treatment strategies that can
effectively work in parallel.
As an initial step in such endeavors, the current
study, within a cohort from a UK national registry of
patients with axial SpA, aimed to 1) determine the
prevalence of FM among patients meeting the ASAS
criteria for axial SpA, and 2) identify clinical and
patient-reported measures that might distinguish axial
SpA patients with comorbid FM.
PATIENTS AND METHODS
The British Society for Rheumatology Biologics Regis-
ter in Ankylosing Spondylitis (BSRBR-AS) is a prospective
cohort study in which patients who meet the ASAS definition
of axial SpA have been recruited from 83 secondary care cen-
ters in the UK, with the first centers recruiting from December
2012. Patients meeting only the ASAS clinical criteria for axial
SpA have been eligible to be recruited from November 2014.
At the time of recruitment into the register, all patients are
naive to anti–tumor necrosis factor (anti-TNF) biologic ther-
apy but may be either starting such therapy (adalimumab,
etanercept, or certulizumab pegol) or continuing on their cur-
rent therapy. The study protocol has previously been published
(14).
For patients starting on biologic therapy, clinical and
patient-reported information is collected at the time of
recruitment and at 3, 6, and 12 months of follow-up. For
patients not taking biologic agents, information is collected at
the time of recruitment and annually thereafter, but these
patients may transfer to the follow-up schedule of patients
receiving biologic therapy if they commence such therapy at a
later date. From September 2015 onward, the patient-
reported data have included the 2011 research criteria for
FM (8). Satisfying the FM research criteria depends on the
presence of widespread pain and somatic symptoms.
Patients in the register were included in the current
analysis if they had completed the 2011 FM research criteria
either at recruitment or at follow-up. We used data from the
time of the first completion of the items in the criteria set.
Information on clinical status at the time of recruitment
allowed us to determine whether patients were known to
meet imaging criteria for axial SpA (the modified New York
criteria for AS [15] and/or the ASAS imaging criteria [13]) or
to not meet such criteria (only meeting the ASAS clinical cri-
teria). Data collected from or measured in each patient
included the BASDAI, the BASFI, the Bath Ankylosing
Spondylitis Metrology Index (16), and the Bath Ankylosing
Spondylitis Global Assessment (17), each scored to provide a
scale from 0 (best) to 10 (worst).
In addition, extraspinal manifestations were assessed,
including uveitis, psoriasis, inflammatory bowel disease, and
swollen and tender joint counts (of 44 joints assessed), in
accordance with the ASAS recommendations for studies of
SpA (18). Quality of life was measured using the 18-item
Ankylosing Spondylitis Quality of Life (ASQoL) scale (17),
providing a score from 0 (good quality of life) to 18 (poor
quality of life). The EuroQol 5-domain (EQ-5D) question-
naire, a 5-item generic scale, was used to assess health-related
quality of life, with scores ranging from 0 (equivalent to
death) to 1 (best possible health), although scores lower than
0 (worse than death) are also possible (19). Other patient-
reported measures collected were a sleep disturbance score
that consisted of 4 items (each scored 0–5; total score 0–20),
with higher scores indicating worse problems with sleep
disturbance (20).
Furthermore, the 11-item Chalder fatigue scale was
used to measure the extent and severity of fatigue. Each item
was scored as 0 or 1, providing a total score of 0–11, with
higher scores indicating worse fatigue. A score of ≥4 is taken
to indicate significant fatigue (21). For assessment of mental
health status, the Hospital Anxiety and Depression Scale
(HADS) (22), a measure of emotional distress, anxiety disor-
ders, and depression in patients with somatic or psychiatric dis-
orders, primary care patients, and the general population, was
used. The HADS has been shown to have a 2-factor structure
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corresponding to the anxiety and depression subscales (23).
Each subscale has 7 items, scored 0–3, providing a total score
for anxiety and for depression of 0–21, with higher scores
indicating higher levels of anxiety or depression. Scale scores
are categorized as 0–7 (normal), 8–10 (mild), 11–14 (moder-
ate), and 15–21 (severe). Patients also completed the Work
Productivity and Activity Impairment Questionnaire: Specific
Health Problem, a validated instrument to measure impair-
ments in work, including both absenteeism and impaired per-
formance while at work (presenteeism) (24).
Height and weight (for the calculation of the body
mass index [BMI]) and the CRP level were measured in each
patient. Furthermore, we constructed a comorbidity index
based on the number of comorbidities reported by the clini-
cian to be present in each patient (including myocardial
infarction, angina, congestive cardiac failure, stroke, hyperten-
sion, diabetes, asthma, chronic bronchitis or emphysema,
peptic ulcer, liver disease, renal disease, tuberculosis, demyeli-
nation, depression, or cancer).
An area-level deprivation score was calculated (the
Index of Multiple Deprivation [IMD]) using comparable offi-
cial government indices from the relevant individual countries
within the UK. These were the English IMD (EIMD), Scottish
IMD (SIMD), and Welsh IMD (WIMD). Each IMD was
based on lower-level census areas, which represent neighbor-
hoods. All indices include income, employment, health, educa-
tion, housing, and crime/community safety. Both the SIMD
and the WIMD include access to services, while in the EIMD,
this is combined with the housing domain. Additionally, the
EIMD adds living environment, and the WIMD adds physical
environment. The IMDs were categorized into quintiles and
standardized to be presented on a scale of 1–5, ranging from
the most deprived (IMD score of 1) to least deprived (IMD
score of 5), in accordance with the practices of the SIMD.
We compared the range of clinical and patient-
reported measures collected from patients with axial SpA
according to whether they met the 2011 research criteria for
FM. Comparisons were carried out using t-tests (continuous
outcomes), 2-sample proportion tests (binary outcomes), chi-
square tests (categorical nonordered outcomes), and nonpara-
metric tests for trend (ordinal outcomes) or for comparison
of distributions (Mann-Whitney U test) as appropriate. The
95% confidence intervals (95% CIs) are given for effect esti-
mates. This analysis used data from the January 2017 version
of the study database.
RESULTS
Participants and prevalence of FM. Among the
2,449 participants in the BSRBR-AS, 1,504 (68% male)
were eligible for the current study, of whom 553
(35.4%) were in the biologics-exposed cohort. The
study population is described in Table 1. Patients had a
median age of 51.2 years, and reported a median time
since symptom onset of 19 years. Among the cohort of
eligible patients, 82.2% of those who had been tested
were HLA–B27 positive, and ~1 in 6 were current
smokers. Most participants (69.2%) met the modified
New York criteria for AS, an additional 26.5% fulfilled
the ASAS imaging criteria but not the modified New
York criteria, and 4.3% fulfilled only the ASAS clinical
criteria. Among the patients, 311 (20.7%) met the 2011
research criteria for FM. The proportion of patients
meeting the FM criteria in each of the respective axial
SpA criteria groups (modified New York criteria, ASAS
imaging criteria but not modified New York criteria,
and ASAS clinical criteria only) was 19.7%, 25.2%, and
9.5% (P = 0.006).
The proportion meeting the FM criteria was
higher among female patients (26.1%, versus 18.2% of
male patients; P < 0.001), but there was no difference
by age group (P = 0.56). HLA–B27–positive patients
were less likely than HLA–B27–negative patients or
untested patients to meet the FM criteria (17.0%, versus
32.1% and 21.7%, respectively; each P < 0.001). The
prevalence of FM did vary by level of area deprivation:
those with IMD scores in the most deprived quintile had
an FM prevalence of 38.0%, those in the least deprived
quintile had an FM prevalence of 13.8%, and in the
intermediate quintiles of IMD, the prevalence of FM
varied from 17.5% to 20.3% (all P < 0.001).
Disease indices for axial SpA. Patients who met
the 2011 FM research criteria had markedly worse
indices of disease (Table 2). They had significantly worse
disease activity, function, metrology, and global status.
Of the 1,034 participants who had a CRP measurement
available, there was no significant difference between
those who did meet FM criteria and those who did not
meet FM criteria in the proportion having a CRP level
that exceeded 1 mg/dl (39.3% versus 38.7%; P = 0.86).
There was no difference in the overall distribution of
Table 1. Characteristics of the study population of 1,504 patients
with axial spondyloarthritis*
Age, median (IQR) years 51.2 (40.1–63.1)
Sex, no. (%) male 1,025 (68.2)
Time since symptom onset, median (IQR) years 19 (9–33)
HLA–B27 status
No. not tested 574
No. positive (% of tested) 765 (82.2)
No. negative (% of tested) 165 (17.8)
CRP, median (IQR) mg/dl 0.55 (0.10–2.00)
Smoking status, no. (%)†
Current smoker 247 (16.7)
Former smoker 578 (39.2)
Never smoker 651 (44.1)
Diagnostic criteria fulfilled, no. (%)
Modified New York criteria 1,041 (69.2)
ASAS imaging criteria but not
modified New York criteria
398 (26.5)
ASAS clinical criteria only 65 (4.3)
* IQR = interquartile range; CRP = C-reactive protein; ASAS =
Assessment of SpondyloArthritis international Society.
† The total number of patients with available data on smoking status
was 1,476.
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CRP level (P = 0.82 by Mann-Whitney U test) nor was
there any difference in CRP level within either the
biologics cohort (P = 0.53) or the non-biologics cohort
(P = 0.76).
Patient-reported measures. Quality of life was
significantly worse in those patients who met the FM
research criteria, regardless of whether quality of life
was measured by a disease-specific measure or a
generic measure (Table 3). Patients meeting the FM
criteria had significantly higher scores on the HADS
anxiety and depression subscales compared to those
who did not meet the FM criteria. Of those who met
the FM criteria, 39.9% were classified as having moder-
ate or severe depression, in comparison to 7.0% of
patients who did not meet the FM criteria (P < 0.001).
The comparable proportions of patients reporting mod-
erate or severe anxiety were 55.3% among those meet-
ing the FM criteria and 17.9% among those not
meeting the FM criteria (P < 0.001). Patients who met
the FM criteria also had higher scores for the extent of
sleep disturbance and levels of fatigue, with the score
exceeding the cutoff value for clinically important fa-
tigue in 79.2% of patients in the FM group compared
to 34.2% in the non-FM group (P < 0.001).
Clinical status and therapy. Patients who satis-
fied the FM research criteria had a higher BMI than
those who did not meet the FM criteria (mean 28.7
kg/m2 versus 27.6 kg/m2, difference of 1.2 kg/m2 [95%
CI 0.3, 2.0]). In addition, those in the FM criteria
group, as compared to those in the non–FM criteria
group, had a greater swollen joint count (mean 0.47
versus 0.21, difference of 0.26 [95% CI 0.03, 0.49])
and greater tender joint count (mean 1.3 versus 0.5,
difference of 0.8 [95% CI 0.4, 1.2]) and were more
likely to report at least 1 comorbidity (36.9% versus
19.9%; P < 0.001). In contrast, there was only a small,
and not statistically significant, excess in the propor-
tion of patients reporting extraspinal manifestations
among patients positive for the FM criteria compared
to those not meeting the FM criteria (for uveitis,
19.0% versus 18.0%; for psoriasis, 9.2% versus 6.4%;
for inflammatory bowel disease, 8.5% versus 7.0%).
Patients meeting the FM research criteria were more
likely to be receiving biologic therapy compared to
those not meeting the FM research criteria (50.5%
versus 31.5%).
Work-related factors. Patients meeting the crite-
ria for FM reported a significantly greater percentage
of work time missed compared to patients not meeting
the FM criteria (15.1% of work time missed versus
2.5% of work time missed, difference of 12.7% [95%
CI 9.7, 15.4%]). Moreover, patients in the FM group
reported that when present at work, their work was
impaired for around one-half (50.8%) of their working
time, in comparison to that reported by the non-FM
group, who reported interference of work around one-
quarter (22.8%) of their working time (difference of
28.1% [95% CI 23.8, 32.3%]).
Table 2. Disease measures in patients with axial spondyloarthritis
according to their meeting or not meeting the 2011 research criteria
for FM*
Disease index










6.7 (6.5, 6.9) 3.6 (3.5, 3.8) 3.1 (2.8, 3.3)
BASFI function 6.6 (6.4, 6.9) 3.7 (3.6, 3.9) 2.9 (2.6, 3.3)
BASMI
metrology
4.2 (4.0, 4.5) 3.6 (3.5, 3.8) 0.6 (0.3, 0.9)
BASG global
health
6.9 (6.7, 7.2) 3.7 (3.6, 3.8) 3.2 (2.9, 3.6)
* FM = fibromyalgia; 95% CI = 95% confidence interval; BASDAI =
Bath Ankylosing Spondylitis Disease Activity Index (scale 0–10);
BASFI = Bath Ankylosing Spondylitis Functional Index (scale 0–10);
BASMI = Bath Ankylosing Spondylitis Metrology Index (scale 0–10);
BASG = Bath Ankylosing Spondylitis Global Score (scale 0–10).
Table 3. Patient-reported measures in patients with axial spondyloarthritis according to their meeting or not meeting
the 2011 research criteria for FM*
Patient-reported measure







ASQoL quality of life score 13.1 (12.7, 13.6) 6.1 (5.8, 6.4) 7.1 (6.4, 7.7)
EQ-5D quality of life score 0.45 (0.42, 0.48) 0.76 (0.74, 0.77) 0.31 (0.33, 0.28)
HADS depression score 9.4 (8.9, 9.8) 4.6 (4.4, 4.8) 4.8 (4.3, 5.2)
HADS anxiety score 11.0 (10.5, 11.5) 6.4 (6.2, 6.6) 4.7 (4.1, 5.2)
SDS sleep 13.4 (12.7, 14.0) 8.1 (7.8, 8.4) 5.3 (4.5, 6.0)
CFS fatigue 6.8 (6.4, 7.2) 2.8 (2.6, 3.0) 4.0 (3.5, 4.4)
* FM = fibromyalgia; 95% CI = 95% confidence interval; ASQoL = Ankylosing Spondylitis Quality of Life (scale 0–18);
EQ-5D = EuroQol 5-domain (scale 0–1 or <1); HADS = Hospital Anxiety and Depression Scale (scale 0–21); SDS =
sleep disturbance score (scale 0–20); CFS = Chalder fatigue scale (scale 0–11).
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DISCUSSION
This UK national study, the largest to have been
conducted to date on the co-occurrence of axial SpA
and FM, demonstrated that ~1 in 5 patients with axial
SpA met the current research criteria for FM. The pro-
portion who met the FM criteria was not higher among
those meeting only the ASAS clinical criteria. Patients
who met the FM criteria had considerably worse
disease indices, had a significantly greater number of
physical and psychological comorbidities, had markedly
poorer quality of life (as measured by generic and
disease-specific scales), and reported a much greater
impact on work than those who did not fulfill the FM
criteria. In contrast, there were no differences in mea-
surements of inflammation and no differences in the
prevalence of most extraspinal disease manifestations.
This multicenter study involved a relatively unse-
lected patient population from secondary care centers,
with recruitment taking place across both specialist and
nonspecialist centers. Moreover, this analysis involved
data from patients who were naive to treatment with
anti-TNF biologic agents, including those who were
newly starting on biologic therapy and those who had
previously started (although all patients, at the time of
recruitment to the register, are naive to biologic ther-
apy). Therefore, the results are likely to represent the
prevalence of those who meet FM criteria in a typical
secondary care population of axial SpA patients.
The key methodologic issue in the current study
is that the 2011 FM research criteria used in this study
have not been validated specifically for use in patients
with axial SpA. Indeed, neither these criteria nor any
other criteria set (nor screening instrument) for FM
have been validated for use in patients with any type of
inflammatory arthritis. The 2010 preliminary diagnostic
criteria for FM (for clinician completion) and the 2011
research criteria for FM (for patient completion) both
require that the patient “does not have a disorder that
would otherwise explain the pain” (7,8). However, this
is challenging for the clinician to determine and almost
impossible for the patient to assess, and it is notewor-
thy that most studies in which the 2010 or 2011 FM
research criteria have been implemented have ignored
this specific requirement, as we have done in the cur-
rent study. Nevertheless, applying these criteria can
identify patients with significant unmet clinical needs.
In a study by Almodovar et al (25), conducted
in Spain, AS patients with an elevated BASDAI/Bath
Ankylosing Spondylitis Radiological Index (BASRI) or
elevated BASFI:BASRI ratio had a high probability of
having a diagnosis of FM. In the same study, there was
also some evidence that patients with AS and FM (in
comparison to those with AS only) responded less well
to management strategies such as nonsteroidal antiin-
flammatory drug therapy. Because of the potential for
distortion of the patient-reported measures that influ-
ence management decisions (such as the BASDAI,
which includes items on both pain and fatigue), it has
been hypothesized that some patients with AS and FM
may inappropriately receive biologic therapy.
Although patients who met the FM research cri-
teria did not demonstrate any differences in the preva-
lence of most extraspinal manifestations of the disease,
they did have a greater number of swollen and tender
joints, which might imply that their disease activity is
greater. The only other study, of which we are aware,
that has used similar FM criteria (the 2010 preliminary
diagnostic criteria for FM, which are the clinician version
of the 2011 FM research criteria) evaluated 91 patients
with axial SpA in clinics in Germany and showed that
34.1% of the patients met the 2010 criteria for FM (26).
In contrast, a much lower proportion of patients (14.3%)
met the ACR 1990 classification criteria for FM. A study
by Bello et al (27) used the self-administered Fibromyal-
gia Rapid Screening Tool (FiRST) (28) to screen 196
patients with a clinical diagnosis of SpA who were
attending a single tertiary care university hospital in
France. They reported a prevalence of FM of 21%.
There was no difference in the prevalence of FM
between patients satisfying the ASAS imaging criteria
and those satisfying the ASAS clinical criteria. Patients
with coexisting FM also had higher BASDAI, spinal
pain, and BASFI scores. There was no statistically signif-
icant difference in the proportion of patients with FM
and those without FM receiving anti-TNF therapy. How-
ever, patients with FM who received anti-TNF therapy
were much less likely to be receiving the same therapy 2
years later (28.1% versus 41.7%; P = 0.01).
The European League Against Rheumatism
(EULAR) has recently revised its recommendations for
the management of FM, and all specific recommenda-
tions are now based on either systematic review or meta-
analysis (29). However, the EULAR working group
noted that there were no trials informing clinicians as to
how to treat FM when it occurs in conjunction with an
inflammatory arthritis; this was therefore made a priority
recommendation for future research. There are effective
therapies for FM (albeit most have modest effect sizes),
including both nonpharmacologic and pharmacologic
approaches. Indeed, there is a consensus, reflected in
recommendations produced at both the national and
the international level, that nonpharmacologic treat-
ments, principally cognitive behavior therapy and exercise,
2148 MACFARLANE ET AL
should constitute first-line therapy (30). Whether such
therapies are as effective in managing FM as a comorbid-
ity alongside best care for an inflammatory condition, and
whether long-term outcomes could be improved, remains
to be determined.
Even in the absence of validated criteria for FM
in patients with inflammatory arthritis, the 2011 FM
research criteria identify a group of axial SpA patients
who have markedly worse patient-reported disease activ-
ity scores, high levels of comorbidity, and clinically
important differences in measures of quality of life. For
example, the ASQoL score of patients who satisfied the
FM criteria (mean 13.1) indicated worse quality of life
than the level deemed acceptable by patients (ASQoL
score of 8.0) (31). Moreover, according to reference
centile charts of the BASDAI, patients who met the cri-
teria for FM had a mean BASDAI score between the
75th and 90th centiles (32). Approximately 4 of 5
patients with axial SpA who met FM criteria had signifi-
cant fatigue, and although there is some circularity in
these observations (for example, fatigue is a single item
in the 2011 FM research criteria), it nevertheless empha-
sizes that the items in the FM criteria set, when taken
together, are identifying a group of patients with very
significant unmet needs. This is particularly true in rela-
tion to work impact, since, among the patients meeting
the criteria for FM, they reported ~15% of work time
missed and impaired performance during more than
one-half of their working time.
In summary, the findings from this study have
shown that an important proportion of patients with
axial SpA meet current research criteria for FM, but the
proportion is no greater among those meeting only the
ASAS clinical criteria. Patients meeting the FM research
criteria have markedly worse disease indices, and this
may therefore represent an unmet and unrecognized
need among patients with axial SpA. A recent large-scale
survey of a patient group conducted by the UK National
Ankylosing Spondylitis Society identified “developing a
greater understanding of the impact of dealing with
other conditions associated with AS” as one of their top
10 research priorities (33). Future research should vali-
date the use of FM research criteria sets in patients with
inflammatory arthritis (including axial SpA) and investi-
gate effective management strategies for patients in
whom these rheumatic conditions co-occur.
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